The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is considering changes to the regulations and funding restrictions stimulant ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...